Press Release
New Clinical Data Reveals MAIA Biotechnology’s THIO Achieves High Efficacy In Advanced Non-Small Cell Lung Cancer Treatment
–News Direct–
By Mangeet Kaur Bouns
Lung cancer remains the top cause of cancer-related deaths in the U.S., accounting for approximately 20% of all cancer fatalities. The American Cancer Society's projections for 2024 highlight the gravity of this issue, with an estimated 234,580 new lung cancer cases and about 125,070 deaths anticipated in the U.S. Of these, nearly 80% to 85% are non-small cell lung cancer (NSCLC) cases, highlighting the urgent need for effective treatments.
MAIA Biotechnology, Inc. (AMEX: MAIA), a clinical-stage biopharmaceutical company focused on developing telomere-targeting immunotherapies for cancer treatment, has unveiled promising new clinical data showcasing the efficacy of its lead product candidate, THIO, in treating NSCLC. This data emerges from a phase 2 clinical trial evaluating THIO in combination with the immune checkpoint inhibitor (CPI) cemiplimab (Libtayo), targeting patients with advanced NSCLC who have not responded to at least two standard-of-care therapies.
In the context of NSCLC, where traditional treatments often fall short, THIO's potential as a first-in-class telomere-targeting agent raises hope. Its ability to disrupt cancer cell telomeres and stimulate immune responses marks a significant advancement in the fight against this devastating disease.
MAIAs Lead Candidate: THIO
THIO is a groundbreaking telomere-targeting agent, currently undergoing phase 2 clinical trials aimed at treating NSCLC with telomerase-positive cancer cells. Telomerase, present in over 85% of human cancers, plays a crucial role in the immortality and proliferation of cancer cells. THIO integrates into telomeres within these cells, disrupting their structure and function leading to rapid tumor cell death.
By inducing telomerase-dependent DNA modification and damage, THIO triggers selective cancer cell death. This process accumulates telomeric damage in cytosolic micronuclei, which then activates both innate (cGAS/STING) and adaptive (T-cell) immune responses. In in vivo cancer models, sequential treatment with THIO followed by PD-(L)1 inhibitors resulted in significant and sustained tumor regression, fostering cancer-specific immune memory.
Key Findings From The Phase 2 THIO-101 Clinical Trial
The phase 2 THIO-101 trial primarily focuses on assessing the safety and tolerability of THIO both as an anticancer agent and as an immune system activator, alongside evaluating its clinical efficacy through overall response rate (ORR).
The trial results are noteworthy. The disease control rate (DCR) for THIO in combination with CPI was 85%, far exceeding the 25-35% DCR typically seen with chemotherapy in third-line treatments. Additionally, 65% of patients surpassed the 5.8-month overall survival (OS) threshold, and 85% exceeded the 2.5-month progression-free survival (PFS) threshold, demonstrating significant clinical benefits. The median survival follow-up time stood at 9.1 months for the cohort of 20 patients.
Optimal dose selection yielded even more impressive outcomes. Patients in third-line receiving 180mg of THIO exhibited a median PFS of 5.5 months, a 75% OS rate at six months and an ORR of 38%, compared to the standard 6-10% ORR for chemotherapy. Notably, 75% of these patients crossed the 5.8-month OS threshold and 88% surpassed the 2.5-month PFS threshold, with a median survival follow-up time of 9.1 months among the eight patients assessed.
Implications And Future Directions
Dr. Vlad Vitoc, chairman and CEO of MAIA, expressed enthusiasm about the trial outcomes, noting, "All exceptional measures of efficacy in our trial to date have exceeded our own expectations and outperformed standard-of-care treatments." He emphasized THIOs potential as a robust, safe and highly effective alternative for patients who have not benefited from chemotherapy and other treatments.
The THIO-101 trial, which completed enrollment ahead of schedule in February, reached its target of 41 patients for the 180 mg dose. This data, which indicates promising disease control and overall response rates, paves the way for further investigation and potential redefinition of cancer treatment protocols.
As THIO-101 data continues to demonstrate favorable disease control and response rates, with full efficacy data anticipated in the latter half of this year, MAIA Biotechnology stands poised to redefine cancer treatment. THIOs promise to transform the standard of care in oncology offers new hope to patients with advanced NSCLC, potentially establishing a new benchmark in cancer therapy.
Featured photo by CI Photos at Shutterstock.
Benzinga is a leading financial media and data provider, known for delivering accurate, timely, and actionable financial information to empower investors and traders.
This post contains sponsored content. This content is for informational purposes only and is not intended to be investing advice.
Contact Details
Benzinga
+1 877-440-9464
Company Website
View source version on newsdirect.com: https://newsdirect.com/news/new-clinical-data-reveals-maia-biotechnologys-thio-achieves-high-efficacy-in-advanced-non-small-cell-lung-cancer-treatment-599831106
Benzinga
COMTEX_453480766/2655/2024-06-07T08:20:02
About Author
Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.
Founded by Gema Cabañero (Forbes Women 2024), a renowned expert in aesthetics and anti-aging, 180 the concept is a Spanish brand at the forefront of advanced nutricosmetic solutions. With over 30 years of dedicated research into the biological and cellular processes of aging, Cabañero has developed the High Precision Aesthetic Method in 6D®, a comprehensive approach that addresses the internal biological factors contributing to external aesthetic concerns. This method integrates insights from nutrition, aesthetics, pharmacy, biology, and chemistry, creating personalized anti-aging regimens tailored to individual needs.
A Visionary Recognized for Scientific Excellence
Through extensive clinical research involving thousands of cases, Gema identified that visible aging signs, such as skin laxity and bone loss, are driven by a cascade of dysfunctions in cellular organelles and macromolecular metabolism imbalances.
Rather than focusing on isolated aging markers, she pioneered a systemic intervention model, integrating insights from 12 key aging hallmarks into the development of the 6-Dimensional Nutritional System. To further strengthen the scientific foundation of her work, Gema collaborated with Nobel Prize-winning scientists George F. Smoot and Randy W. Schekman, as well as scientists associated with CSIC research groups. These collaborations cement 180 the concept as a leader in scientific anti-aging innovation.
H6 2.0 ‘s New Efficacy: The Three-Dimensional Anti-Aging Network
At the core of H6 Capsules 2.0 is the Three-Dimensional Anti-Aging Network, designed to support facial bone structure longevity through three fundamental pillars:
1.Stabilization
The upgraded HGH Activation Complex 2.0 works to stimulate endogenous growth hormone production. This addresses age-related bone density loss, reinforcing facial structure and providing a stable foundation for youthful contours.
2.Lifting
The proprietary Isometric-Lifting Group restores dermal-fascial anchoring, enhancing the skin-fiber elasticity and mechanical stability necessary for a firmer, sculpted facial contour.
3.Cellular Noutriment
The Cell Plant System 2.0 targets mitochondria, optimizing cellular metabolism and reversing mitochondrial dysfunction. This process improves skin vitality and helps maintain a youthful appearance by addressing the root causes of aging at the cellular level.
Evidence: Clinically Proven Results
The effectiveness of H6 Capsules 2.0 has been validated by SGS, a global leader in scientific testing and certification. In a 28-day clinical study with 33 female participants, aged 30 to 60, visible contour lifting was achieved, with significant improvements in skin firmness and elasticity. The results confirm:
– Visible contour lifting in just 28 days, with measurable improvements in skin firmness and elasticity.
This clinical validation provides real-world evidence that further solidifies 180 the concept’s position as a leader in nutricosmetic innovation and underscores the integration of scientific expertise in developing anti-aging solutions.
Shaping the Future of Nutricosmetic Solutions
The launch of H6 Capsules 2.0 marks a significant shift in 180 the concept’s approach, from general oral beauty to a highly specialized strategy focusing on bone structure anti-aging. By introducing its Six-Dimensional Nutritional Positioning System, the brand leads the next evolution in the nutricosmetic industry, setting a new standard for precision anti-aging.
This approach moves beyond superficial skincare and aims for a more holistic rejuvenation, with a focus on scientific rigor, Nobel Prize collaborations, and real-world clinical validation.
For more details, visit 180 the concept Official Website.
About Author
Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.
Turkey-based brokerage firm KlasFX has introduced a slew of upgrades and changes for a better trading experience. These include updated backend technology and focused features.
In line with its mission of providing quality services and continual improvements, KlasFX has recently unveiled upgrades to its platform. The updates reinforce its core belief in transparency and security while adhering to user-friendly innovations.
Latest Updates On KlasFX Platform
KlasFX stays committed to its vision of customer satisfaction. Accordingly, the platform has executed several updates and changes that reflect its focus on user-centric services.
KlasFX has completely redesigned its trading platform. Engineered from the ground up, the new platform prioritizes speed and efficiency, delivering a frictionless trading experience for all users. This significant upgrade underscores KlasFX’s commitment to providing a superior trading environment.
KlasFX provides unwavering support with its dedicated Customer Support team, available 24/5 during trading hours. The team is not only reactive to inquiries but also proactively offers guidance to ensure traders receive prompt assistance throughout their trading journey, fostering a confident trading environment.
Traders at KlasFX can now leverage their positions up to 500x in a variety of markets. This gives them exceptional flexibility and allows investors to tap into the potential for increased returns. This expansion of leverage options offers traders dynamic tools for market participation.
Other KlasFX Features
Beyond its core trading functionalities, KlasFX has also integrated a suite of features that are tailored to protect user funds and enhance their trading journey.
KlasFX has implemented a robust suite of technical and financial security measures, designed to align with stringent industry standards and regulatory compliance. This commitment to security ensures a protected trading environment for all clients. By adhering to best practices and rigorous protocols, KlasFX reinforces its dedication to safeguarding user assets and maintaining the highest levels of operational integrity.
In a demonstration of appreciation for its valued clientele, KlasFX has introduced a range of bonus and rewards initiatives. These programs cater to both new traders embarking on their trading journey and existing clients who have contributed to the platform’s success. This initiative further solidifies KlasFX’s commitment to providing a rewarding and engaging trading experience.
About KlasFX
KlasFX is a Turkey-based multi-asset trading platform that offers a superior trading experience. It provides a diverse range of trading instruments that investors can leverage to their advantage. The platform operates with transparency and an investor-focused outlook, and has been serving the Turkish market for several years.
Driven by a ‘trader-first’ approach, KlasFX continually invests in infrastructure and feature enhancements designed to optimize performance and build trust. Prioritizing reliability and security, KlasFX adheres to stringent industry standards to ensure safe and efficient trading. Through these efforts, KlasFX aims to redefine the forex trading landscape and solidify its position as a trusted and dependable brokerage.
KlasFX is the source of this content. This Press Release is for informational purposes only. The information does not constitute investment advice or an offer to invest.
About Author
Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.
Press Release
Hinfo: Flexible Food Ordering Integration, Additional Languages and New Deluxe Translation Package
Hinfo is launching Version 3.9 of their digital compendium today with 4 new major features. Hinfo is introducing the flexibility for hotels to integrate their preferred mobile food ordering provider that communicates with their own PMS/POS system. Hinfo introduces 4 new supported languages, all with Auto Translate support. A new Auto Translate Deluxe package has been introduced, making it faster and more cost effective for properties to cater for most guest preferred languages. Hinfo now offers a bold option for all available fonts.
Australia, 8th Apr 2025 – Mobile food ordering has become the new normal in the last few years, including QR code ordering at tables, when dining out. Hinfo saw an opportunity that allows for room service orders to be automated via each hotel’s PMS/POS system of choice. Hinfo now provides hotels the opportunity to add a link to their own food ordering system for guests to use.
“Combining both our cost-effective Hinfo digital compendium with your preferred mobile ordering system, results in the best overall experience for your staff and guests.” Says Neil Houlston, Founder of Hinfo. “This is designed to complement our existing built-in food ordering service and allows for more automated processes for staff, without being locked into a particular PMS and compendium setup.”
Hinfo are adding support for Māori, Thai, Filipino and Vietnamese to their growing list of supported languages in their digital hotel compendium, now totalling 18 languages + English.
These languages utilise the Auto Translate service built into Hinfo and the automatic detection on guests devices in their preferred language, if supported by each property.
Hinfo saw an opportunity to work towards their goal of creating a truly multilingual hotel compendium, that is both cost effective and fast to implement.
Extending beyond the option to purchase each language separately, Hinfo have introduced their Auto Translate Deluxe package, which includes all languages they support.
“Auto Translate has greatly reduced the time and cost of providing multilingual compendiums for all property types and sizes. Our deluxe offering takes this even further.” Says Neil Houlston, Founder of Hinfo. “Translating a single subject of details in all 18 languages we currently support, now only takes 30-40 seconds and all for one low monthly price.”
Hinfo have also included a couple of new fonts in addition to a bold option for each one currently available.
This allows for headings to have clearer contrast next to all details listed.
All these updates are designed to improve communication with all guests, allow each property to be more personalized and allow any food ordering system to be added with ease, to increase revenue and automate processes for each property.
For more information about the Hinfo digital hotel compendium service or to try out these new features in a demo, please visit the Hinfo website or contact the company directly.
Website: https://www.hinfo.com
About Author
Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.
180 the concept Introduces H6 2.0 – Redefining Facial Contour Anti-Aging
Trading Reimagined: KlasFX Upgrades User Experience with an Investor-First Approach
Hinfo: Flexible Food Ordering Integration, Additional Languages and New Deluxe Translation Package
Bay Smokes Maintains Quality Amid Legislative Changes in the Hemp Industry
Benzinga Money Article Discusses How to Become Part of the 12% of Retirees Who Have Achieved the Recommended $550,000 Minimum Retirement Savings Threshold
Apu Apustaja Conquers New York with Lively Street Ads, Including Times Square Billboard
-
Press Release3 days ago
Crescent Petroleum and Dana Gas reach 500 MMboe cumulative production from Khor Mor field, announce major growth and development plans
-
Press Release1 week ago
Top 5 Benefits of Using ESD Fabric in Electronics Manufacturing
-
Press Release6 days ago
Ernesto Morales Speaks Out on the Future of Community Engagement
-
Press Release3 days ago
Dr. Akira Olsen Releases New Book Focused on Personal Growth and Mental Wellness for Gen Z and Millennials
-
Press Release6 days ago
Costa Bella Realty Group Sets the Standard for Real Estate Excellence in Hollywood, FL
-
Press Release3 days ago
Dr. Akira Olsen Releases New Book Focused on Personal Growth and Mental Wellness for Gen Z and Millennials
-
Press Release4 days ago
Founded by Kenyan-American Josephine K. Stegeman, Human Rights Vision Group Unveils Expanded Global Empowerment & Social Progress Services
-
Press Release1 week ago
Benefits of OTDS System for Investment Casting Industry